



An SMC Ltd. Company

# "PATIENT-CENTRICITY" – THE IMPORTANCE OF HUMAN FACTORS IN THE PANDEMIC ERA

In this article, Marcus Agunloye, Senior Human Factors Engineer & Industrial Designer at Oval Medical, and Asmita Khanolkar, Senior Director, Cambridge Pharma, SMC Technical Strategy & Commercialization, discuss how patient-centricity is at the heart of drug delivery device design and innovation, and how the global pandemic has highlighted the importance of patient-centric development in this field.

The drug delivery device market is expected to grow tremendously, bringing novel technologies and therapies to life. The key factors driving this innovation peak include a trend towards moving care out of hospitals and into patients' homes, adoption of smart devices, predictive data analytics, targeted therapeutics and personalised medicine. Patient focus is a common theme in all these

drivers. As we begin this decade, it is clear that patient-centricity is at the heart of all innovation and one of the most important considerations throughout the development process. However, there is a lot of work still to be done in this field to truly understand the concept, process and what exactly the success criteria are towards a patient-centric development. The pandemic has opened our eyes to the importance of human factors considerations even further.

## MARKET TRENDS

Global trends continue to move medical care from hospitals to homes, with the

"There is a lot of work still to be done in this field to truly understand the concept, process and what exactly the success criteria are towards a patient-centric development. The pandemic has opened our eyes to the importance of human factors considerations even further."

pandemic threat of covid-19 the push for virtual care, longer time between hospital visits, and at-home care for chronic diseases has increased. An example is the transfer of chemotherapy treatment from hospitals to homes, which has led to a requirement for subcutaneous delivery of cancer treatments as opposed to intravenous delivery in a hospital setting. This trend is generating a need for devices for self-administration that can deliver large volumes of formulation and drug containers that can withstand high pressures in order to provide acceptable delivery times. Successful high-pressure delivery device systems will determine the success of this important transition from hospital to home.



**Marcus Agunloye**  
Senior Human Factors Engineer  
& Industrial Designer  
T: +44 1223 736220  
E: marcus.agunloye@ovalmedical.com

**Oval Medical Technologies**  
Unit 3, Enterprise 3930  
Cambridge Research Park  
Beach Drive  
Waterbeach  
Cambridge  
United Kingdom

[www.ovalmedical.com](http://www.ovalmedical.com)



**Asmita Khanolkar**  
Senior Director, Cambridge Pharma,  
SMC Technical Strategy  
& Commercialization  
T: +1 978 422 6800  
E: asmita.khanolkar@smcltd.com

**SMC Ltd**  
18 Independence Drive  
Devens  
MA 01434  
United States

[www.smcltd.com](http://www.smcltd.com)

“The three effects of the covid-19 pandemic, namely isolation, virtual care and remote learning, are all elements that amplify the problems of self-administered devices.”

Smart devices are an area of opportunity to enhance user engagement with their treatment process. Using a smartphone or other digital device can offer the patient an expanded user interface, including useful functionality such as dose tracking, reminders and training information, and can also offer opportunities for the prescriber to understand adherence when care is moved to the home. However, this relies on two things from the patient – access to technology and their engagement with the smart system. Whilst the adoption of smartphones is becoming more and more widespread, there are still patient populations that may struggle to afford an up-to-date smartphone, so understanding patient access to technology must be a key consideration in the inclusion of this type of technology into a drug delivery device.

Whilst adding further functionality and data information for the user through a connected device may seem like an easy way to improve the patient experience, it is important to understand if the patient wants to engage with this. Some patient populations may find the steps required to set up a connected device confusing or taxing, or may have a general reluctance towards technology that might make a connected device a barrier to adherence rather than a motivator. Overall, there may be compelling use cases for the integration of digital systems into drug delivery devices, but it is important to understand how the patient population will respond to it by exploring the area with them and considering the full range of costs and benefits associated with this type of integration before moving forward with it.

#### HUMAN FACTORS CONSIDERATIONS IN THE PANDEMIC

Human factors considerations are even more important than ever in identifying specific patient needs, particularly in the

current global pandemic. The three effects of the covid-19 pandemic, namely isolation, virtual care and remote learning, are all elements that amplify the problems of self-administered devices. Under the conditions of the pandemic, patients couldn't be trained in hospitals and overall access to healthcare practitioners (HCPs) was limited, yet more and more therapies started moving towards home care. The pandemic emphasised the need for intuitive devices that need only very minimal training. Crisis devices are often used by a carer, a teacher or even a passer-by, and again, in such cases, intuitive-to-use devices are needed for effective dosing.

In addition, the effect of isolation and emotion on the use of the device requires a non-threatening, welcoming, integrated functional approach. The pandemic also highlighted the effects of disparity where technology may not be universally available. Not everyone is technology savvy, and digital literacy may be a big factor in the correct use of the device. In addition, diversity factors are more exaggerated with remote site limitations, spread of information and patient involvement. It is clear that the one-size-fits-all approach does not work with diverse patient populations, including paediatric and geriatric populations, and a range of users from patient to carer to community pharmacist, and a variety of dose regimens are required.

#### ELEMENTS OF A "PATIENT-CENTRIC" MODEL

The four important areas of considerations for human factors include patient safety, patient outcomes, patient adherence or compliance, and finally, the overall patient

experience (Figure 1). Patient safety and therapy outcomes are the first layers of consideration. Current complaints vary with the application and include both crisis and chronic use. For life threatening diseases, obviously this can be profoundly serious and have serious consequences. For emergency-use devices, it is imperative that the accurate dose is injected at the correct depth, intramuscularly or subcutaneously. Some of the human factors considerations in these applications focus around patient populations. Patient physiology is different in children compared with adults, and important considerations of needle-to-muscle depth accuracy repeatability when overcoming population diversity is an important factor.

Some of the challenges with glass containers include breakage and repeatability issues due to siliconised rubber. In high-pack glass syringes, patients have experienced variability of injection times, resulting in wet injections. In the case of biologic drugs, this can potentially cause immunological response due to wet injections. Other impurities such as tungsten in needle-staked glass containers can pose issues for the stability of delicate drugs, such as biologics, and result in degradation of the drug and unwanted therapy outcomes. Finally, use errors are on the rise due to the pandemic and lack of training, this demands intuitive devices.

Patient adherence and overall experience are the second layers of considerations and equally important. Particularly with self-administered devices, ease of use becomes a priority. Devices need to be easy to use without training, or with minimal training, should promote adherence, be non-intimidating and perform robustly and reliably every time for a positive overall experience.




Figure 1: Elements of a patient-centric model.

“Using patient insights on cognitive and emotional needs, lifestyle, population diversity, technology access and adoption skills, reliability and sustainability can help add further benefits to the therapy.”

Long-acting injectables provide a better overall patient experience due to a reduced number of injections. However, it is important to focus on adherence and if the patient will remember to administer their injection regularly each month, and to create a feedback loop so the prescriber knows that the patient is receiving their treatment. Training decay can also be an issue if the patient only uses the autoinjector once a month – will they be able to remember how to use it again a month later?




Figure 2: Incorporating patient needs for intuitive autoinjector designs.

First and foremost, the best approach to solve this is to make the device as simple and intuitive to use as possible. This can also be supported with training the patient, such as having an HCP guide the patient through the first few injections and by having robust information

available for the patient to support themselves, such as training videos and clear instructions for use.

A patient-centric model requires additional elements with the patient at the heart of the thought process, and designing around the patient. Using patient insights on cognitive and emotional needs, lifestyle, population diversity, technology access and adoption skills, reliability and sustainability can help add further benefits to the therapy. Oval’s approach to device development combines a deep understanding of the patient’s needs, coupled with the technical needs when developing patient-centric autoinjectors that can be customised to deliver a wide range of drug formulations, including fragile molecules for both subcutaneous and intramuscular injection with high viscosities and a wide range of delivered volumes (Figure 2).

Philosophy

<b>Intuitive</b> Clear & predictable	<b>Usability</b> Ease of use, durable & robust	<b>Human</b> Approachable, engaging & friendly	<b>Dynamic</b> Contemporary, seamless, hard to copy	<b>Calm</b> Natural, holistic & uplifting
---	---	---	--	--

Figure 3: Key design features with a human approach.

Key Characteristics

1. Curved Top Body
2. Tactile Waist
3. Cap smile
4. Cap Tactile Proudness
5. Frosted Cap
6. Front View Symmetric Body
7. Crisp Edges (For smaller devices)
8. Tension Viewing window
9. Down Force Dexterity Friendly



Figure 4: Human factors attributes applied to design.

PATIENT-CENTRIC DESIGN THINKING

To put the user case at the heart of the process, the device design must satisfy functional, cognitive, aesthetic and emotional balance. This requires flexibility in the design space for both the inside and outside of the device. Moulded primary drug containers provide both flexibility of container size and shape, and control of tolerances for reliability of repeated use. The inside mechanics need to deliver the therapy in optimised delivery time, depth and bolus size.

The outside is equally important for key design features with a human approach, such as those shown in Figure 3. Figure 4 shows the human factors attributes applied to the product design.






Figure 6: Human factors process.

**PATIENT-CENTRIC DEVELOPMENT STRATEGY**

These early-stage activities then form a crucial input for the rest of the human factors process. Early concepts are refined and narrowed down and, as the autoinjector design develops, subsequent formative evaluations can be undertaken with increasingly high-fidelity prototypes. This feedback loop of design development and user interaction allows both the

development of a thorough understanding of the users’ interactions with the device and use-related risk, while also continuing a conversation with the patient and user population about their needs beyond just the delivery of their medication (Figure 6).

As the device reaches maturity, a thorough understanding of the use of the device user interface and its associated risks has been developed, with mitigations applied where necessary, ready for validation. At the same time, this process maintains the

user and patient’s voice throughout, putting focus not just on the device but on the wider environment and scenarios that affect the patient’s experience, resulting in an end product that is both safe and effective for the user, and optimised to the needs of the patient throughout their treatment journey.

**PATIENT USABILITY STUDIES**

Formative usability studies are an important part of the feedback loop in patient-centric development, providing insights into device handling and patient preference. The use steps of the device can be tested, with prototype variants of the device provided with packaging, labelling and instructions for use, allowing the evaluation of injection site preference, observation of use errors for safety, improvement areas for the user interface, effectiveness of training and population diversity factors. Examples of feedback measurements may include successful dose delivery and an understanding of the visual and audible feedback provided by the device. The feedback from these studies can then be used to inform device design, developing a device that users can understand and feel comfortable using.

Late-stage user studies can then be used to further analyse the design of the user interface once it has matured. Through the use of tools such as use-related risk analysis, critical tasks can be identified, and, by testing these with the intended user population, it can be determined if the device is safe and effective for use and ready for human factors validation. Alongside this, late-stage user studies can also be used to verify that the design decisions made in response to early-stage observations work for the patient population’s wider needs through discussion on the use of the device.

This approach was taken in the case study shown in Figure 7, where three user studies were conducted on early-stage device designs. The results from these studies eventually led to the design of the ArQ platform, with its user interface undergoing further refinement through another two user studies (Figure 8).

Through this process, findings were made, both about how the device functions and how it fits into the patient’s daily life. In the early stages, user feedback led to the development of the key user interface elements, now found across Oval’s platforms, such as the audible and visual feedback mechanisms. The process also involved testing an autoinjector variant tailored to patient populations with low manual dexterity, the learnings from which

“Patient input will always be key to developing the best possible autoinjector. By involving the patient in the process early and often, you have the best chance of uncovering their full range of needs and ensuring that what you are designing responds to them.”




Figure 7: Design evolution through multiple user studies and patient populations.



Figure 8: Optimised user interface design elements for ArQ.




Figure 9: Optimised user interface design elements for ArQ-Bios high viscosity/volume.




Figure 10: "Easy-to-use" steps for a patient-centric design.

influenced Oval's approach to building an understanding of patient's specific needs and customising devices to patient populations (Figure 9).

**PATIENT FEEDBACK**

Patient input will always be key to developing the best possible autoinjector. By involving the patient in the process early and often, you have the best chance of uncovering their full range of needs and ensuring that what you are designing responds to them. By making sure this input is implemented throughout the design process, you can reach validation with a device that is not just safe and effective to use but fits properly into the patient's life and eases some of the issues they may have previously experienced with their treatment (Figure 10).

## ABOUT THE COMPANIES

**Oval Medical Technologies** is a drug delivery company whose patient-centric autoinjector platforms enable pharmaceutical companies to deliver a wide range of drug formulations for both subcutaneous and intramuscular injection. Oval's flexible, robust drug delivery platforms can be tailored precisely, providing unprecedented scope for pharmaceutical companies to address the needs of current patient populations and develop and market new products. With its patented integrated primary drug container technology at their core, Oval's devices are safe, reliable and easy to use in their target patient populations. The company is certified to ISO 13485 (2016).

**SMC** is a single source partner to commercialisation for the healthcare industry with over 30 years of experience in device manufacturing. SMC's global cGMP manufacturing facilities across the US, UK, Costa Rica and India, offer moulding, assembly, fill-finish and automated package integration provide clinical and commercial product for an "end-to-end" integrated solution. SMC

provides product services from initial concept through the final packaged device; including programme management, design and development, product manufacturing, clinical

manufacturing, electronics integration and global supply chain management specialising in drug delivery devices, diagnostics and medical devices.

## ABOUT THE AUTHORS

**Marcus Agunloye**, Senior Human Factors Engineer & Industrial Designer, Oval Medical Technologies, is a human factors engineer, with experience working in industrial design and human factors in the medical device industry. He joined Oval in 2017, where his focus has been on improving patient experience and safety through user interface design. He graduated with a BA in industrial design and technology from Brunel University (UK).

**Asmita Khanolkar**, Senior Director, Cambridge Pharma, SMC Technical Strategy & Commercialization, has a master's degree in materials science & engineering from Worcester Polytechnic Institute in Worcester, MA, US. With over 24 years of manufacturing experience specialising in the medical device and pharmaceutical industry, she has managed various device projects from concept to commercial launch. Her product portfolio includes single-use, wearable and implantable devices, and drug device/device-biologic combination products for drug delivery, biotech and pharmaceutical applications. Ms Khanolkar has held various engineering and management roles in new product development, manufacturing engineering, advanced quality planning, operations, supply chain and product life cycle management. Her current responsibilities include technical strategy and commercialisation of innovative technology platforms for drug delivery and fill-finished combination product.

